<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1998.
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Transition period from ________ to _______
Commission File Number: 0-28424
CARDIOGENESIS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 77-0352469
- ----------------------------- ---------------------------------
(State or other (I.R.S. employer
jurisdiction of identification No.)
incorporation or
organization)
540 OAKMEAD PARKWAY
SUNNYVALE, CALIFORNIA 94086
(Address of principal executive
offices, including zip code)
(408) 328-8500
(Registrant's telephone number,
including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
The number of shares of Common Stock outstanding as of April 30, 1998 was
12,193,908.
-1-
<PAGE> 2
CARDIOGENESIS CORPORATION
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets as of March 31, 1998 3
and December 31, 1997
Condensed Consolidated Statements of Operations for the three 4
months ended March 31, 1998 and 1997
Condensed Consolidated Statements of Cash Flows for the three 5
months ended March 31, 1998 and 1997
Notes to Condensed Consolidated Financial Statements 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION 7
AND RESULTS OF OPERATIONS
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 11
PART II. OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS 11
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K 12
SIGNATURE 13
INDEX TO EXHIBITS 14
</TABLE>
-2-
<PAGE> 3
CARDIOGENESIS CORPORATION
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
------- -------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 4,079 $ 6,047
Available-for-sale securities 12,340 24,469
Accounts receivable, net 815 3,293
Inventories 1,382 1,109
Other current assets 1,956 1,751
------- -------
Total current assets 20,572 36,669
Property and equipment, net 1,808 1,529
Available-for-sale securities, non-current 21,236 10,019
Other assets 24 23
------- -------
Total assets $43,640 $48,240
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 4,794 $ 3,944
Deferred revenue -- 150
------- -------
Total liabilities 4,794 4,094
Contingencies (Note 3)
Stockholders' equity 38,846 44,146
------- -------
Total liabilities and stockholders' equity $43,640 $48,240
======= =======
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
-3-
<PAGE> 4
CARDIOGENESIS CORPORATION
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
---------------------------
1998 1997
-------- --------
<S> <C> <C>
Sales $ 850 $ 1,583
Cost of sales 703 1,131
-------- --------
Gross profit 147 452
-------- --------
Operating expenses :
Research and development 3,811 3,254
General and administrative 1,338 771
Sales and marketing 1,141 801
-------- --------
Total operating expenses 6,290 4,826
-------- --------
Operating loss (6,143) (4,374)
Interest income and other, net 555 779
-------- --------
Net loss $ (5,588) $ (3,595)
======== ========
Net loss per common share
and per common share
- assuming dilution $ (0.46) $ (0.30)
======== ========
Shares used in computing
net loss per common share
and per common share
- assuming dilution 12,134 11,982
======== ========
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
-4-
<PAGE> 5
CARDIOGENESIS CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
Three Months Ended March 31,
----------------------------
1998 1997
-------- --------
<S> <C> <C>
Cash flows from operating activities:
Net loss $ (5,588) $ (3,595)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 111 115
Amortization of deferred compensation 115 137
Changes in assets and liabilities:
Accounts receivable 2,478 (335)
Inventories (273) (67)
Other current assets (205) 259
Accounts payable and accrued expenses 850 880
Deferred revenue (150) (370)
-------- --------
Net cash used in operating activities (2,662) (2,976)
-------- --------
Cash flows from investing activities:
Purchase of available-for-sale securities (19,224) (5,378)
Maturities of available-for-sale securities 20,136 19,950
Acquisition of property and equipment (390) (75)
Other assets (1) --
-------- --------
Net cash provided by investing activities 521 14,497
-------- --------
Cash flows from financing activities:
Proceeds from issuance of Common Stock, net 173 89
-------- --------
Net cash provided by financing activities 173 89
-------- --------
Net (decrease) increase in cash and cash equivalents (1,968) 11,610
Cash and cash equivalents, beginning of period 6,047 2,080
-------- --------
Cash and cash equivalents, end of period $ 4,079 $ 13,690
======== ========
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
-5-
<PAGE> 6
CARDIOGENESIS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - INTERIM CONSOLIDATED FINANCIAL STATEMENTS
These interim consolidated financial statements are unaudited, but have
been prepared in accordance with generally accepted accounting principles for
interim information and with the instructions to Form 10-Q. In the opinion of
management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation of financial position, results of operations
and cash flows at the dates and for the periods presented have been included.
The interim financial information herein is not necessarily indicative of
results for any future period. The interim consolidated financial statements
should be read in conjunction with the audited financial statements and the
notes thereto for the fiscal year ended December 31, 1997 included in the
Company's Form 10-K filed with the Securities and Exchange Commission.
NOTE 2 - INVENTORIES
Inventories consisted of the following:
<TABLE>
<CAPTION>
MARCH 31 DECEMBER 31
1998 1997
------ ------
(in thousands)
(unaudited)
<S> <C> <C>
Raw materials $ 749 $ 736
Finished goods 633 373
------ ------
$1,382 $1,109
====== ======
</TABLE>
NOTE 3 - CONTINGENCIES
In September 1996, the Company filed an action for declaratory relief against
PLC Systems, Inc. of Canada and its wholly-owned U.S. subsidiary, PLC Medical
Systems, Inc., (collectively, "PLC"), seeking a judgment that PLC's United
States patent No. 5,125,926 (the "PLC Patent") to a certain heart-synchronized
pulsed laser system is not infringed, is invalid and is unenforceable. In the
suit, filed in the United States District Court for the Northern District of
California, the Company also requested the Court to enter judgment that the
Company's Transmyocardial Revascularization (TMR) systems do not infringe the
PLC Patent. In October 1996, PLC responded to the complaint. In its response,
PLC took the position that the PLC Patent has been infringed by the Company, but
made no further claims. In September 1997, the Company filed an amended
complaint asking the Federal District Court to consider evidence of inequitable
conduct in the U.S. Patent Office while the PLC Patent was being obtained by
PLC. The amended complaint asserts that the PLC Patent is invalid and
unenforceable because material prior work of another party was withheld from the
Patent Office. Trial is set to begin on January 11, 1999.
On February 9, 1998, PLC submitted the PLC Patent to the U.S. Patent Office
seeking reissue on the basis that the PLC Patent as granted is "wholly or partly
inoperative or invalid."
In January 1997, the Company filed an Opposition to a European Patent owned
by PLC (the "European Patent") that is a counterpart to the PLC Patent. The
Opposition seeks to have the European Patent declared invalid. The Company
believes it has meritorious positions with respect to the invalidity of the
European Patent and intends to pursue the Opposition proceeding vigorously.
-6-
<PAGE> 7
In September 1997, the Company was served with a complaint filed by PLC in
Munich, Germany alleging that the Company and its former German sales agent have
infringed EP 0 553 576, a European counterpart of the PLC Patent. The Company
has referred the complaint to patent counsel and is proceeding in its defense on
the basis of non-infringement.
NOTE 4 - COMPUTATION OF NET LOSS PER COMMON SHARE AND PER COMMON SHARE -
ASSUMING DILUTION
The Company adopted Financial Accounting Standards Board Statement No. 128
"Earnings Per Share" and the provisions of the Securities and Exchange
Commission Staff Accounting Bulletin (SAB) No. 98, and accordingly all prior
periods have been restated. Net loss per common share and per common share-
assuming dilution are computed using the weighted average number of shares of
common stack outstanding. Common equivalent shares from stock options are
excluded from the computation of diluted net loss per common share as their
effect is antidilutive.
Stock options to purchase shares of common stock at prices ranging from to
per share were outstanding at March 31, 1998, but were not included in the
computation of diluted net loss per common share because they were antidilutive.
The aforementioned stock options could potentially dilute earnings per share in
the future.
NOTE 5 - RECENT ACCOUNTING PRONOUNCEMENTS
Effective March 31, 1998 the Company has adopted Statement of Financial
Accounting Standards No. 130, "Reporting Comprehensive Income." SFAS No. 130
establishes standards for the reporting and display of comprehensive income and
its components in a full set of general purpose financial statements.
Comprehensive income is defined as the change in equity of a business enterprise
during a period, resulting from transactions and other events and circumstances
from nonowner sources. As the components of comprehensive income for the Company
are not material, the additional reporting and display of comprehensive income
and its components have not been reflected in the accompanying financial
statements.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Report contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking
statements involve a number of risks and uncertainties, including the factors
described throughout this Report, and in the Company's Form 10-K filed with the
Securities and Exchange Commission, particularly the section entitled
"Management's Discussion and Analysis of Financial Condition and Results of
Operations -- Risk Factors." The actual results the Company achieves may differ
materially from any forward-looking statements due to such risks and
uncertainties. The Company has identified by an asterisk (*) various sentences
within this Report which contain such forward-looking statements, and words such
as "believes", "anticipates", "expects", "intends" and similar expressions are
intended to identify forward-looking statements, but are not the exclusive means
of identifying such statements. The Company undertakes no obligation to revise
any forward-looking statements to reflect events or circumstances that may arise
after the date of this Report. Readers are urged to carefully review and
consider the various disclosures made by the Company in this Report and in the
-7-
<PAGE> 8
Company's 1997 Form 10-K filed with the Securities and Exchange Commission that
attempt to advise interested parties of the risks and factors that may affect
the Company's business.
OVERVIEW
Since its inception, CardioGenesis has been primarily engaged in the design,
development, and marketing of its transmyocardial revascularization ("TMR")
systems. The Company has only a limited operating history and has experienced
significant operating losses since its inception. The Company incurred a net
loss of $5.6 million in the three months ended March 31, 1998. The development
and potential commercialization of the Company's products will continue to
require significant research and development, regulatory, sales and marketing,
manufacturing and other expenditures. *Operating losses are expected to continue
at least through 1999 as the Company continues to perform research and
development, to fund clinical trials in support of regulatory and reimbursement
approvals, and to expand its marketing and sales activities in the U.S. and
internationally by supporting Boston Scientific Corporation ("BSC"), the
exclusive distributor in international markets. There can be no assurance that
the Company's TMR systems will ever generate significant revenues or that the
Company will achieve or sustain profitability.
The research, manufacture, sale and distribution of medical devices such as the
Company's TMR systems are subject to numerous regulations imposed by
governmental authorities, principally the Food and Drug Administration ("FDA")
and corresponding state and foreign agencies. The regulatory process is lengthy,
expensive and uncertain. FDA approval of a Pre-market Approval ("PMA")
application is required before any of the Company's TMR systems can be marketed
in the United States. Securing FDA approvals and clearances will require
submission to the FDA of extensive clinical data and technical information.
Also, many foreign governments and the European Union also have review processes
for medical devices. The Company has received CE Mark approval to market its
intraoperative TMR (ITMR(TM)) System and percutaneous TMR (PMR(TM)) System in
the European Union. The CE Mark is granted to companies whose products meet the
essential requirements of the European Medical Device Directive ("MDD") and
provides the regulatory approval necessary for commercialization in Europe. The
Company will be subject to continued supervision by regulators and will be
required to report any serious adverse incidents to the appropriate authorities.
The Company also will be required to comply with additional national
requirements that are outside the scope of the MDD. *The Company plans to
continue to seek regulatory approvals to allow for marketing and distribution of
its products in international markets.
The Company commenced clinical trials of its ITMR System in October 1995 and
began clinical trials of its PMR System in November 1996. Clinical trials of the
Company's thoracoscopic TMR (TTMR(TM)) System have not commenced.
In July 1996, the Company began a Phase II clinical trial under an
investigational device exemption ("IDE") that allowed a prospective, randomized,
multi-center clinical trial of its ITMR System in "no-option" patients with
severe coronary artery disease ("CAD"). Enrollment in the Phase II, randomized,
no-option trial is now complete. The Company has commenced submission of data
and information to the FDA on the Company's ITMR System. *The Company plans to
continue submitting information and updates to the FDA throughout the next six
to nine months and to respond to periodic inquiries from the FDA with respect to
review of such data and information. *This proactive and collaborative approach
to submissions provides the Company with a means for frequent reviews by the FDA
of information required for PMA as well as discussions regarding the ITMR
System.
In August 1996, the Company received an IDE from the FDA and has begun a major
clinical study of its intraoperative ITMR System used as an adjunctive therapy
to coronary artery bypass graft ("CABG") surgery in patients with severe angina
who are only partially treatable by CABG. The adjunct to CABG clinical trials
are on-going.
Clinical trials for the Company's PMR System commenced in Europe in November
1996. In January 1998, the Company received the CE Mark approval for use of its
PMR System in the European Community. In July 1997, the Company received an IDE
from the FDA which allows a multi-center clinical trial of the PMR system to
treat angina in no-option patients at up to twelve clinical sites in the U.S.
Enrollment for the U.S. clinical trial sites has
-8-
<PAGE> 9
begun and the trials are ongoing. In addition to treating the first U.S. human
patient on July 31, 1997, more than 150 human patients have been treated with
the Company's PMR system.
The Company recorded sales of $850,000 for the first three months of 1998 from
sales of its ITMR Systems, PMR Systems and disposable probes and catheters to
its international distributor, BSC and to clinical trial sites in the U.S. The
Company recognizes product revenues upon shipment of its products to customers
and fulfillment of acceptance terms, if any, and when no significant contractual
obligations remain outstanding. Deferred revenue consists of shipments that have
been made which are subject to limited rights of return or other contingencies.
*The Company anticipates its revenues from product sales over the next several
years will be primarily derived from international sales to BSC. *As a result,
the revenue levels of the Company are and will be dependent on the efforts of
BSC and the demand for the Company's TMR Systems in the international market.
*Any such international sales will be subject to a number of risks, including
foreign currency fluctuations, economic or political instability, foreign tax
laws, shipping delays, various tariffs and trade regulations and restrictions
and foreign medical regulations, any of which could have a material adverse
impact on the Company's revenues.
*Results of the Company's operations have varied and are expected to fluctuate
significantly from quarter to quarter depending on numerous factors, including:
(i) reliance on BSC; (ii) demand for the Company's products, new product
introductions by the Company or its competitors or transitions to new products;
(iii) the timing of orders and shipments; (iv) the degree of acceptance of TMR
therapy by the medical community; (v) competition, including pricing pressures;
(vi) potential third-party patent infringement claims; (vii) the timing of
regulatory and third-party reimbursement approvals; (viii) expansion of the
Company's manufacturing capacity and the Company's ability to manufacture its
products efficiently; (ix) the timing of research and development expenses,
including clinical trial-related expenditures; and (x) seasonal factors
affecting the number of procedures performed. *Due to such fluctuations in
operating results, period-to-period comparisons of the Company's operating
results are not necessarily meaningful and should not be relied upon as
indicators of likely future performance.
RESULTS OF OPERATIONS
Sales. Sales of the Company's ITMR Systems, PMR Systems and disposable products
for commercial use in Europe and for use at clinical trial sites in both the
U.S. and Europe decreased approximately $733,000 to $850,000 for the three
months ended March 31, 1998 from $1.6 million for the same period in 1997. This
reduction in sales is due to the limited availability of reimbursement for TMR
procedures in Europe and constraints placed on capital purchases by various
governments outside the U.S.
Cost of Sales. Cost of sales consists of direct and indirect costs of providing
ITMR Systems, PMR Systems and disposal products to customers. Cost of sales was
approximately $703,000, or 83% of sales, for the three months ended March 31,
1998 and $1.1 million, or 71% of sales, for the same period in 1997. The
increase in cost of sales as a percent of sales from 1997 to 1998 was primarily
due to the allocation of fixed overhead costs over fewer units.
Research and Development Expenses. Research and development expenses increased
approximately $557,000 to $3.8 million for the three months ended March 31, 1998
from $3.3 million for the same period in 1997. The increase in 1998 was
primarily due to increased activity in the clinical trials and continued
investment in research in the field of TMR. *The Company expects research and
development expenses to continue to increase at least through 1998 as the
Company continues to enroll patients in its ongoing clinical trials, initiates
additional clinical trials, and continues to invest in TMR mechanism research.
General and Administrative Expenses. General and administrative expenses
increased approximately $567,000 to $1.3 million for the three months ended
March 31, 1998 from $771,000 for the same period in 1997. The increase in 1998
was primarily due to increased finance and administration personnel costs to
support the Company's growth, increased legal fees associated with research and
development agreements and legal fees related to the lawsuit by the Company
against PLC seeking a judgment that a PLC patent is invalid and unenforceable.
*The Company expects that general and administrative expenses will continue to
increase at least through 1998.
-9-
<PAGE> 10
Sales and Marketing Expenses. Sales and marketing expenses increased
approximately $340,000 to $1.1 million for the three months ended March 31, 1998
from $801,000 for the same period in 1997. The increase in 1998 was primarily
due to increased sales and marketing costs associated with the distribution of
the ITMR and PMR systems in Europe. *The Company expects that sales and
marketing expenses will continue to increase in 1998 as the Company expands
clinical studies, conducts physician training, and supports the sales and
marketing activities of BSC.
Interest Income and Other, Net. Interest income and other, net decreased
$224,000 to $555,000 for the three months ended March 31, 1998 from $779,000 for
the same period in 1997. The decrease is primarily due to decreases in interest
income in 1998 attributable to decreases in the Company's cash and cash
equivalents and short-term investments balances.
Deferred Compensation Expense. The Company recorded deferred compensation
expense of approximately $1.4 million and $874,000 with respect to options to
purchase Common Stock granted and Preferred Stock issued during 1996 and 1995,
respectively. Deferred compensation expense is being amortized over the vesting
period of the options, which is generally four years. Compensation expense of
$115,000 and $137,000 was recognized for the three months ended March 31, 1998
and 1997, respectively.
LIQUIDITY AND CAPITAL RESOURCES
The Company has funded its operations since inception primarily through the
private sale of capital stock and interest income on proceeds from private
financings as well as proceeds and interest thereon from its initial public
offering in May 1996. Through March 31, 1998, the Company had raised
approximately $77.2 million from the sale of stock, net of issuance costs.
Net cash used in the Company's operations was $2.7 million and $3.0 million for
the three months ended March 31, 1998 and 1997, respectively. The Company's
acquisition of property and equipment was $390,000 and $75,000 for the three
months ended March 31, 1998 and 1997, respectively. The increase in property and
equipment acquired in 1998 is due to the purchase of additional laser units used
for research and development purposes.
At March 31, 1998, the Company had cash, cash equivalents and available-for-sale
securities, totaling $37.7 million. *The Company plans to finance its operations
and capital needs principally from cash, cash equivalents, and
available-for-sale securities, and, to the extent available, from bank and lease
financing, and believes these sources of cash will be sufficient to fund its
operations through 1998. However, the Company's future liquidity and capital
requirements will depend upon numerous factors, including the level of sales of
the Company's products generated by BSC in major and emerging international
markets; market acceptance of, and demand for the Company's products; the
Company's clinical research and product development programs; the receipt of,
and the time required to obtain regulatory clearances and approvals; the
resources the Company devotes to the development, manufacture and marketing of
its products; the resources required to hire and develop a direct sales force in
the United States, and to expand manufacturing capacity; facilities
requirements; and other factors. *Although the Company believes its current
levels of cash, cash equivalents, and available-for-sale securities, together
with cash generated from operations, will provide adequate funding for its
operations and capital requirements through 1998, the Company may be required to
raise additional funds through public or private debt or equity financings,
collaborative relationships, bank facilities or other arrangements. There can be
no assurance the Company will not require additional funding sooner or that such
additional funding, if needed, will be available on terms attractive to the
Company, or at all. *Any additional equity financing may be dilutive to
stockholders, and debt financing, if available, may involve restrictive
covenants.
IMPACT OF THE YEAR 2000 ON INFORMATION SYSTEMS
The Company relies on computers and computer software to run its business, as do
its vendors, suppliers and customers. These computers and computer software may
not be able to properly recognize the dates commencing in
-10-
<PAGE> 11
the Year 2000. The Company has not completed an assessment of the impact this
may have on its businesses and does not have a reasonable basis to conclude
whether the impact of the Year 2000 dates will or will not materially affect
future results. To date the Company has not found any material impact which may
result from failure of its computers and computer software or that of its
vendors, suppliers, and customers. *However, the Company plans to make an
assessment of this during 1998, and, if appropriate, develop an action plan to
correct it.
RECENT ACCOUNTING PRONOUNCEMENTS
In June 1997, the FASB issued Statement of Financial Accounting Standards No.
131, "Disclosure about Segments of an Enterprise and Related Information." SFAS
No. 131 requires publicly-held companies to report financial and other
information about key revenue-producing segments of the entity for which such
information is available and is utilized by the chief operating decision maker.
Specific information to be reported for individual segments includes profit or
loss, certain revenue and expense items and total assets. A reconciliation of
segment financial information to amounts reported in the financial statements
would be provided. SFAS No. 131 is effective for the Company for the year ending
December 31, 1998. The Company operates in one business segment; namely, the
research, development, manufacture and sale of cardiovascular surgical devices.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
PART II. OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
On May 21, 1996, the Company commenced an offering of Common Stock and issued
3.0 million shares. The aggregate offering price of the shares sold was $60.0
million. Expenses and underwriting discounts and commissions incurred in
connection with the issuance totaled $5,533,000. Net offering proceeds to the
Company were $54,467,000. The table below shows all amounts from the effective
date of the registration statement to March 31, 1998. All amounts are rounded to
the nearest $1,000.
<TABLE>
<CAPTION>
Direct or indirect Direct or indirect
payments to directors, payments to others
officers, general partners
of the issuer or their
associates; to persons
owning ten percent or more
of any class of equity
securities of the issuer;
and to affiliates of the
issuer
---------------------------- ----------------------------
(A) (B)
---------------------------- ----------------------------
<S> <C> <C>
Construction of plant, - -
building and facilities
Purchase and installation of - -
machinery and equipment
Purchase of real estate - -
Acquisition of other - -
business(es)
Repayment of indebtedness - -
Working capital - 20,891,000
Temporary investment - 33,576,000
============================ ============================
Net offering proceeds $0 $54,467,000
============================ ============================
</TABLE>
-11-
<PAGE> 12
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The following exhibits are filed as part of this report on
Form 10-Q:
Number Description
------ -----------
27.01 Financial Data Schedule
(b) Reports on Form 8-K
None.
-12-
<PAGE> 13
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CARDIOGENESIS CORPORATION
(Registrant)
Date : May 15, 1998 By: /s/ Richard P. Powers
-----------------------------------
Richard P. Powers
Chief Financial Officer, Vice
President of Finance and
Administration, and Secretary
(Duly Authorized Officer, Principal
Financial Officer, and Principal
Accounting Officer)
-13-
<PAGE> 14
INDEX TO EXHIBITS
EXHIBIT
- -------
27.01 Financial Data Schedules
-14-
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A) THE
COMPANY'S FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 1998 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH (B) FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 4,079
<SECURITIES> 12,340
<RECEIVABLES> 815
<ALLOWANCES> 0
<INVENTORY> 1,382
<CURRENT-ASSETS> 20,572
<PP&E> 1,808
<DEPRECIATION> 0
<TOTAL-ASSETS> 43,640
<CURRENT-LIABILITIES> 4,794
<BONDS> 0
0
0
<COMMON> 38,846
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 43,640
<SALES> 850
<TOTAL-REVENUES> 850
<CGS> 703
<TOTAL-COSTS> 703
<OTHER-EXPENSES> 6,290
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (5,588)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,588)
<EPS-PRIMARY> (0.46)
<EPS-DILUTED> (0.46)
</TABLE>
